DAPA-HF trial detailed results for Farxiga
DAPA-HF is the first outcomes trial with an SGLT2 inhibitor, Farxiga for treatment for patients with HFrEF HOPE for people living with heart failure has been presented on the 1st September 2019 BST 1.30pm at ESC Congress in Paris 2019. Detailed results of the Phase III DAPA-HF trial show all the primary endpoints achieved with […]